Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Khalil, Asma ^a   Muttukrishna, Shanthi ^b   Harrington, Kevin ^a   Jauniaux, Eric ^b  

^a HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; METHYLDOPA; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; FLT1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PLACENTA PROTEIN; PRODUCT PLACENTA GROWTH FACTOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG INDICATION; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; PLACENTA; PREECLAMPSIA; PROTEIN BLOOD LEVEL; UNITED KINGDOM; DOPPLER FLOWMETRY; HYPERTENSION; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PREGNANCY; PREGNANCY COMPLICATION;

ANGIOGENESIS INHIBITORS; ANTIGENS, CD; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; METHYLDOPA; NEOVASCULARIZATION, PATHOLOGIC; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREGNANCY PROTEINS; RECEPTORS, CELL SURFACE; ULTRASONOGRAPHY, DOPPLER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 50649083428     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002766     Document Type: Article

References (43)

1. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350(7): 672-683.
2. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, et al. (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355(10): 992-1005.
3. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, et al. (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12(6): 642-649.
4. Maynard SE, Min JY, Merchart J, Lim KH, Li J, et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111(5): 649-658.
5. Ahmad S, Ahmed A (2004) Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95(9): 884-891.
6. Rana S, Karumanchi SA, Levine RJ, Venkatesha. S, Rauh-Hain JA, et al. (2007) Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50(1): 137-142.
7. Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, et al. (2005) Urinary placental growth factor and risk of preeclampsia. JAMA 293(1): 77-85.
8. Romero R, Nien JK, Espinoza J, Todem D, Fu W, et al. (2008) A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 21(1): 9-23.
9. Bujold E, Romero R, Chaiworapongsa T, Kim YM, Kim GJ, et al. (2005) Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. J Matern Fetal Neonatal Med 18(1): 9-16.
10. Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, et al. (2000) Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 80(4): 443-454.
11. Kendall RL, Wang G, Thomas KA (1996) Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226(2): 324-328.
12. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, et al. (2005) Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 26(7): 563-573.
13. Raab U, Velasco B, Lastres P, Letamendia A, Cales C, et al. (1999) Expression of normal and truncated forms or human endoglin. Biochem J 339: 579-588.
14. Raab U, Lastres P, Arevalo MA, Lopez-Novoa JM, Cabanas C, et al. (1999) Endoglin is expressed in the chicken vasculature and is involved in angiogenesis. FEBS Lett 459(2): 249-254.
15. Roy H, Bhardwaj S, Yla-Herttuala S (2006) Biology of vascular endothelial growth factors. FEBS Lett 580(12): 2879-2887.
16. Vuorela P, Hatva E, Lymboussaki A, Kaipainen A, Joukov V, et al. (1997) Expression of vascular endothelial growth factor and placenta growth factor in human placenta. Biol Reprod 56(2): 489-494.
17. Celik-Ozenci C, Akkoyunlu G, Kayisli UA, Arici A, Demir R (2003) Localization of vascular endothelial growth factor in the zona pellucida of developing ovarian follicles in the rat: a possible role in destiny of follicles. Histochem Cell Biol 120(5): 383-390.
18. Celik-Ozenci C, Akkoyunlu G, Korgun ET, Savas B, Demir R (2004) Expressions of VEGF and its receptors in rat corpus luteum during interferon alpha administration in early and pseudopregnancy. Mol Reprod Dev 67(4): 414-423.
19. Maglione D, Guerriero V, Viglietto G, li-Bovi P, Persico MG (1991) Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 88(20): 9267-9271.
20. Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova, O, et al. (1993) Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PIGF), are transcribed from a single gene of chromosome 14. Oncogene 8(4): 925-931.
21. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, et al. (1995) Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11(8): 1569-1579.
22. Clark DE, Smith SK, Licence D, Evans AL, Charnock-Jones DS (1998) Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J Endocrinol 159(3): 459-467.
23. Tordjman R, Delaire S, Plouet J, Ting S, Gaulard P, et al. (2001) Erythroblasts are a source of angiogenic factors. Blood 97(7): 1968-1974.
24. Failla CM, Odorisio T, Cianfarani F, Schietroma C, Puddu P, et al. (2000) Placenta growth factor is induced in human keratinocytes during wound healing. J Invest Dermatol 115(3): 388-395.
25. Hollborn M, Tenckhoff S, Seifert M, Kohler S, Wiedemann P, et al. (2006) Human retinal epithelium produces and responds to placenta growth factor. Graefes Arch Clin Exp Ophthalmol 244(6): 732-741.
26. Head GA, Chan CK, Burke SL (1998) Relationship between imidazoline and alpha2-adrenoceptors involved in the sympatho-inhibitory actions of centrally acting antihypertensive agents. J Auton Nerv Syst 72(2-3): 163-169.
27. Head GA (1999) Central imidazoline- and alpha 2-receptors involved in the cardiovascular actions of centrally acting antihypertensive agents. Ann N Y Acad Sci 881: 279-286.
28. Falkay G, Melis K, Kovacs L (1994) Correlation between beta- and alpha-adrenergic receptor concentrations in human placenta. J Recept Res 14(3-4): 187-195.
29. Szelenyi J, Kiss JP, Puskas E, Szelenyi M, Vizi ES (2000) Contribution of differently localized alpha 2- and beta-adrenoceptors in the modulation of TNF-alpha and IL-10 production in endotoxemic mice. Ann N Y Acad Sci 917: 145-153.
30. Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GY (2001) Plasma levels of vascular endothelial growth factor and its soluble receptor (sFlt-1) in essential hypertension. Am J Cardiol 87(6): 805-807, A9.
31. Brown MA, Lindheimer MD, de Swiet M, Van AA, Moutquin JM (2001) The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 20(1): IX-XIV.
32. Roberts JM, Pearson G, Cutler J, Lindheimer M (2003) Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension 41(3): 437-45.
33. He Y, Smith SK, Day KA, Clark DE, Licence DR, et al. (1999) Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol. 13(4): 537-545.
34. Henning M, Rubenson A (1971) Evidence that the hypotensive action of methyldopa is mediated by central actions of methylnoradrenaline. J Pharm Pharmacol 23(6): 407-11.
35. Day MD, Roach AG, Whiting RL (1973) The mechanism of the antihypertensive action of -methyldopa in hypertensive rats. Eur J Pharmacol 21(3): 271-280.
36. Van Zwieten, PA, Timmermans PB, Van BP (1984) Role of alpha adrenoceptors in hypertension and in antihypertensive drug treatment. Am J Med 77(4A): 17-25.
37. Bottari SP, Vokaer A, Kaivez E, Lescrainier JP, Vauquelin GP (1983) Differential regulation of alpha-adrenergic receptor subclasses by gonadal steroids in human myometrium. J Clin Endocrinol Metab 57(5): 937-941.
38. Falkay G, Kovacs L (1994) Expression of two alpha 2-adrenergic receptor subtypes in human placenta: evidence from direct binding studies. Placenta 15(6): 661-668.
39. Khan ZP, Ferguson CN, Jones RM (1999) alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia 54(2): 146-165.
40. Gilman AG (1987) G proteins: transducers of receptor-generated signals. Annu Rev Biochem 56: 615-649.
41. Morishita K, Johnson DE, Williams LT (1995) A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression. J Biol Chem 270(46): 27948-27953.
42. Wakiya Y, Begue A, Stehelin D, Shibuya M (1996) A cAMP response element and an Ets motif are involved in the transcriptional regulation of flt-1 tyrosine kinase (vascular endothelial growth factor receptor 1) gene. J Biol Chem 271(48): 30823-30828.
43. Muthig V, Gilsbach R, Haubold M, Philipp M, Ivacevic, T, et al. (2007) Upregulation of soluble vascular endothelial growth factor receptor 1 contributes to angiogenesis defects in the placenta of alpha 2B-adrenaceptor deficient mice. Circ Res 101(7): 682-691.